Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Uterine macrophages as treatment targets for therapy of premature rupture of membranes by modified ADSC-EVs through a circRNA/miRNA/NF-κB pathway

Fig. 2

Changes in CircRNAs in the uteri of normal control (NC) and PROM model mice. A CeRNA profiling showing significant changes in circRNA expression in the uteri between NC and PROM model mice. B Heat map of the top 20 circRNAs showing significant changes following PROM occurrence. C Schematic representation of cir2047 structure and sponged miR-760-5p and miR-1931. D and E Expression of cir2047 measured by qPCR in the decidua and F4/80-positive cells. F Co-expression of F4/80 and cir2047 in uterine tissue detected by in situ hybridization and IF. Scale bar = 50 μm. G Binding sites of cir2047 and miRNAs were predicted by bioinformatics algorithms and subsequently mutated to verify interactions. H and I Effects of cir2047-sponged miR-1931 and miR-760 were validated using luciferase reporter vector assays. Full-length cir2047 and sequences containing different mutated variants of the miRNA-binding site (cir2047-M) were used to detect the suppressed effects of miR-1931 and miR-760. J IP of AGO2 from F4/80-positive cells co-transfected with AGO2 and either miR-1931, miR-760, or miR-146a (negative control). Empty vector served as the AGO2-related negative control. Cir2047 and ACTB mRNA levels were quantified by qPCR and relative IP/input (total cellular RNA) values were plotted; **p < 0.01; ns, not significant

Back to article page